Standard BioTools Regains Nasdaq Compliance, Eliminating Delisting Risk
LAB sits 32% above its 52-week low of $0.87.
Summary
Standard BioTools has successfully regained compliance with Nasdaq's minimum bid price rule, resolving the deficiency notice it received on April 20, 2026. This positive development, also reported in an 8-K filing today, removes a significant delisting risk that had been an overhang for the company. Regaining compliance enhances investor confidence and ensures the stock's continued listing on a major exchange.
At the time of this announcement, LAB was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $448.9M. The 52-week trading range was $0.87 to $1.72. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.